ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

Carcinogenesis, Epidemiology, Smoking RFAs Get DCCP Board Okay

June 12, 1981

Trials Approved by NCI CTEP For the Month of April

April 27, 2012

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

Also in this 12-page issue: GM Cancer Research Foundation awards annual prizes to four scientists.

June 4, 2004

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009